Good
Partially Aligned
Patient Risk:
Medium
Summary
Most content aligns with the provided FDA label excerpts for indications, drug class, administration route (IV for injection and oral for tablets), contraindication, and several administration/side-effect-related concepts. However, multiple mechanism-of-action details and the specific FDA approval timing claim are not supported by the provided labeling excerpts, and the side-effect list includes items not substantiated in the supplied label text.
Category Scores
Accurate Statements
Nuzyra (omadacycline) is a tetracycline-class antibiotic.
Provided label excerpt notes: Contraindications/Warn. sections reference 'tetracycline class' similarity (e.g., 'NUZYRA is structurally similar to tetracycline class of antibacterial drugs').
Nuzyra can be administered intravenously (IV).
Dosage and Administration excerpt includes 'NUZYRA for Injection' with '200 mg IV infusion...' and preparation/administration instructions for IV.
Nuzyra can be administered orally.
Dosage and Administration excerpt includes 'NUZYRA Tablets' with oral regimens (e.g., CABP: '300 mg orally once daily'; ABSSSI: '450 mg orally once a day on day 1 and day 2').
Nuzyra is approved for the treatment of community-acquired bacterial pneumonia (CABP) in adults.
Indications and Usage 1.1: CABP indicated for 'adult patients'.
Nuzyra is approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.
Indications and Usage 1.2: ABSSSI indicated for 'adult patients'.
Nuzyra is contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs (and excipients).
Contraindications section: 'contraindicated in patients with known hypersensitivity to omadacycline or tetracycline class antibacterial drugs, or to any of the excipients'.
Unsupported Statements
Nuzyra works by inhibiting bacterial protein synthesis.
The provided excerpts do not describe a mechanism of action.
Nuzyra binds to the bacterial 30S ribosomal subunit.
No such mechanistic detail appears in the provided label excerpts.
By binding to the bacterial 30S ribosomal subunit, Nuzyra interferes with the binding of transfer RNA to messenger RNA.
No such mechanistic detail appears in the provided label excerpts.
Interference with transfer RNA binding to messenger RNA halts the production of vital proteins.
No such mechanistic detail appears in the provided label excerpts.
Nuzyra received FDA approval for CABP and ABSSSI in October 2018.
No FDA approval date/timing is included in the provided label excerpts.
Nuzyra is manufactured by Melinta Therapeutics.
No manufacturer information is present in the provided excerpts.
Common side effects of Nuzyra include nausea.
The provided label excerpts do not list nausea as a 'common side effect'. Only a general adverse reactions statement is provided without specific frequency/details.
Common side effects of Nuzyra include vomiting.
The provided label excerpts do not list vomiting as a 'common side effect'.
Common side effects of Nuzyra include diarrhea.
The provided label excerpts discuss 'Clostridioides difficile-associated diarrhea' as a warning/precaution, but do not provide a frequency-based 'common side effect' list including diarrhea.
Other reported side effects of Nuzyra can include headache.
No headache adverse reaction details are included in the provided excerpts.
Other reported side effects of Nuzyra can include dizziness.
No dizziness adverse reaction details are included in the provided excerpts.
Other reported side effects of Nuzyra can include infusion-related reactions.
No infusion-related reaction adverse reaction details are included in the provided excerpts.
Nuzyra has expanded spectrum of activity against certain Gram-positive, Gram-negative, and atypical pathogens compared to some older tetracyclines.
The provided excerpts do not include comparative spectrum claims.
Contradictions
Important Omissions
No dosage regimen, dosing duration (7 to 14 days), or dosing route-specific instructions (e.g., IV infusion duration; oral fasting/dairy/antacid restrictions) were provided in the claims list.
Importance:
Moderate
No mention of key safety warnings relevant to tetracycline-class risks (tooth discoloration/enamel hypoplasia; inhibition of bone growth; C. difficile-associated diarrhea; hypersensitivity) in the provided claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several detailed claims (mechanism-of-action, approval timing, and frequency-based side effects) are unsupported by the provided label excerpts; unsupported side-effect frequency statements could mislead risk perception. Indications and routes of administration align with the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Mechanism-of-action details, FDA approval timing, manufacturer attribution, and specific 'common side effects' are not supported by the supplied labeling excerpts.
Suggested Improvement
Limit label-aligned statements to indications (adult CABP and ABSSSI), routes/dosage forms (IV injection and oral tablets with fasting/food interaction instructions), and label-supported safety warnings; remove or qualify unsupported mechanistic, approval-date, manufacturer, and frequency-based adverse event claims unless supported by additional label text.